The numbers · Doses studied
Thymosin Alpha-1 Dosage in the Research Literature
What was administered, to which populations, by which route — reported as research data, never as a recommendation.
The gist
This page describes how Thymosin Alpha-1 has been dosed in studies — it is not a how-to and gives no personal instructions. In the trials, the peptide is almost always given as a small injection just under the skin (subcutaneous). The most common research regimen is 1.6 mg twice a week, used for chronic hepatitis [4]. Single doses across studies have ranged from about 0.8 to 6.4 mg [4]. It does not stay in the blood long — roughly a two-hour half-life after a subcutaneous shot, returning toward baseline within about a day. Everything below is written in the third person and tied to the population and route used in each study. No dose here is a suggestion for any person.
Thymosin alpha 1 dosage as studied
Across the clinical literature, the thymosin alpha 1 dosage most often reported is 1.6 mg subcutaneous twice weekly — the standard chronic-hepatitis regimen [4]. A comprehensive review records single doses studied across a 0.8–6.4 mg range, with multiple-dose regimens of 1.6–16 mg given over five to seven days [4]. In the sepsis trials the protocol was more intensive: 1.6 mg subcutaneous every 12 hours for five to seven days (ETASS and TESTS) [2][3]. COVID-19 cohort studies used 1.6 mg subcutaneous daily [6]. These are documented study protocols in defined patient populations, reported here strictly as research data.
Thymosin alpha 1 injection: the subcutaneous route
The thymosin alpha 1 injection route in essentially every clinical trial is subcutaneous — a small injection into the fat layer under the skin. Mechanistic studies have used in-vitro and murine (intraperitoneal) routes, but human data is subcutaneous [5]. The peptide is supplied lyophilized (freeze-dried) because, as a highly acidic peptide with an isoelectric point around 4.2, it is degraded by tissue and circulating aminopeptidases and must be reconstituted before use [4].
Half-life and clearance
After subcutaneous injection in human volunteers, Thymosin Alpha-1 shows an elimination half-life of roughly two hours, with peak blood levels around one to two hours and a return toward baseline within about 24 hours; its volume of distribution is consistent with distribution into extracellular fluid. It does not extensively bind plasma proteins [4]. The short half-life is one reason clinical regimens repeat dosing every 12 hours in acute settings while using twice-weekly schedules in chronic hepatitis.
Why no human dosing guidance appears here
Thymosin Alpha-1 is not FDA-approved in the United States, and all dosing above is drawn from trials and approved-abroad clinical settings in specific patient populations [4]. Extrapolating those numbers to unregulated or self-administered use is not supported by the evidence and falls outside any approved indication. This site reports what was studied; it does not tell any individual what to take.